Hence, while anti-IL-7Rα mAb treatment demonstrated preclinical efficacy, preventing relapse in patients suffering from chronic inflammatory and/or autoimmune diseases will probably require iterative administrations. The gene discussed is IL7R; the disease is autoimmune disease.